Decision support for precision oncology: Evolving from monotherapy to genomically informed combinations

CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer

Systems immunology in immuno-oncology

Highlights from WIN 2019

Goals of the WIN Consortium

Rapidly changing landscape of precision medicine in Japan

Use of platform studies for the evaluation of innovative combinations in solid tumours and haematologic malignancies

Implementing national cancer control plans

Tackling the increase in cancer cases worldwide

Getting high level care to low and middle income countries

How will ASCO combat cancer disparities?

Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL